The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer. We retrospectively ...The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer. We retrospectively reviewed the medical records of 20 patients with stage IV non-small-cell lung cancer. The patients had progressive disease after standard antitumor therapy and subsequently received intravenous albumin-bound paclitaxel at the dose of 100 mg/m2 in weekly schedule. Cumulative findings showed that the overall response rate was 30.0%, the disease control rate amounted to 40%, and the 1 year survival rate was 30%. In addition, the median time to progression and the median survival time reached 5 and 10 months, respectively. Meanwhile, no severe hypersensitivity reactions and grade 4 adverse effects were reported. In summary, weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy.展开更多
Objective： To observe the efficacy and safety of albumin-bound paclitaxel （ABP） monotherapy in treating recurrent advanced non-small-cell lung cancer （NSCLC）. Methods： We retrospectively analyzed the short-term ...Objective： To observe the efficacy and safety of albumin-bound paclitaxel （ABP） monotherapy in treating recurrent advanced non-small-cell lung cancer （NSCLC）. Methods： We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed. Results： Of these 21 patients, the best overall response was partial response （PR） in 6 patients （28.6%）, stable disease （SD） in I0 patients （47.6%）, and progressive disease （PD） in 5 patients （23.8%）. The overall response rate （ORR） was 28.6% and the disease control rate （DCR） （PR ＋ SD） was 76.2%. The median progression-flee survival （PFS） was 4.0 months （95% CI, 5.0-7.0 months）. The main grade 3/4 toxicities included neutropenia （11.1%）, peripheral nerve toxicity （5.6%）, muscle and joint aches （5.6%）, and fatigue （5.6%）. Conclusions： The ABP monotherapy can achieve good objective response in advanced NSCLC patients who have previously received multiple cycles of treatment and be well tolerated.展开更多
This paper reports that at a newly constructed small-angle x-ray scattering station of Beijing Synchrotron Radia- tion Facility, the topological shape of ligand-free bovine serum albumin in solution has been investiga...This paper reports that at a newly constructed small-angle x-ray scattering station of Beijing Synchrotron Radia- tion Facility, the topological shape of ligand-free bovine serum albumin in solution has been investigated. An appropriate scattering curve is obtained and the calculated value of the gyration radius is 31.2~=t=0.25 ~_ （11=0.1 nm） which is co- incident with other ones＇ results. It finds that the low-resolution structure models obtained by making use of ab initio reconstruction methods are fitting the crystal structure of human serum albumin very well. All of these results perform the potential of the beamline to apply to structural biology studies. The characteristics, the defects, and the improving measures of the station in future are also discussed.展开更多
目的探讨术前C反应蛋白与白蛋白比值(C-reactive protein to albumin ratio,CAR)对非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的预测价值。方法选取自2017年8月~2019年7月于南京医科大学附属苏州医院接受肺癌根治术的300...目的探讨术前C反应蛋白与白蛋白比值(C-reactive protein to albumin ratio,CAR)对非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的预测价值。方法选取自2017年8月~2019年7月于南京医科大学附属苏州医院接受肺癌根治术的300例NSCLC患者的临床资料,通过受试者工作特征(receiver operating characteristic,ROC)曲线确定最佳临界值,分为高CAR组和低CAR组,分析不同CAR表达水平的NSCLC患者临床病理特征,采用Kaplan-Meier法绘制生存曲线并用Log-rank检验评估差异,COX比例风险模型分析影响NSCLC预后的因素。结果术前CAR预测NSCLC患者预后的ROC曲线下面积(area under the curve,AUC)为0.710,临界值为0.02。CAR与年龄、病理类型、T分期、是否淋巴结转移、临床分期、肿瘤直径、是否行术后化疗相关(P<0.05)。CAR低水平组患者总生存期(overall survival,OS)与无病生存期(disease-free survival,DFS)均长于CAR高水平组,差异有统计学意义(P<0.001)。COX多因素风险回归显示,CAR升高是NSCLC患者OS、DFS的独立危险因素(P<0.05)。结论术前CAR可作为非小细胞肺癌患者有效的预后指标,CAR升高提示预后不良。展开更多
文摘The purpose of this study was to evaluate the efficacy and safety of nanoparticle albumin-bound paclitaxel as a rescue regimen in the treatment of patients with advanced non-small-cell lung cancer. We retrospectively reviewed the medical records of 20 patients with stage IV non-small-cell lung cancer. The patients had progressive disease after standard antitumor therapy and subsequently received intravenous albumin-bound paclitaxel at the dose of 100 mg/m2 in weekly schedule. Cumulative findings showed that the overall response rate was 30.0%, the disease control rate amounted to 40%, and the 1 year survival rate was 30%. In addition, the median time to progression and the median survival time reached 5 and 10 months, respectively. Meanwhile, no severe hypersensitivity reactions and grade 4 adverse effects were reported. In summary, weekly-administered albumin-bound paclitaxel seems to be an effective and safe regimen for elderly patients with stage IV non-small-cell lung cancer who were refractory to conventional therapy.
文摘Objective： To observe the efficacy and safety of albumin-bound paclitaxel （ABP） monotherapy in treating recurrent advanced non-small-cell lung cancer （NSCLC）. Methods： We retrospectively analyzed the short-term efficacy and toxicities of ABP monotherapy in treating 21 patients who had previously undergone multiple cycles of therapy for their advanced NSCLC in our hospital since 2010. The treatment-related survival was also analyzed. Results： Of these 21 patients, the best overall response was partial response （PR） in 6 patients （28.6%）, stable disease （SD） in I0 patients （47.6%）, and progressive disease （PD） in 5 patients （23.8%）. The overall response rate （ORR） was 28.6% and the disease control rate （DCR） （PR ＋ SD） was 76.2%. The median progression-flee survival （PFS） was 4.0 months （95% CI, 5.0-7.0 months）. The main grade 3/4 toxicities included neutropenia （11.1%）, peripheral nerve toxicity （5.6%）, muscle and joint aches （5.6%）, and fatigue （5.6%）. Conclusions： The ABP monotherapy can achieve good objective response in advanced NSCLC patients who have previously received multiple cycles of treatment and be well tolerated.
基金Project supported by the Chinese Academy of Science Innovation Key Project (Grant No KJCX2-SW-N06)
文摘This paper reports that at a newly constructed small-angle x-ray scattering station of Beijing Synchrotron Radia- tion Facility, the topological shape of ligand-free bovine serum albumin in solution has been investigated. An appropriate scattering curve is obtained and the calculated value of the gyration radius is 31.2~=t=0.25 ~_ （11=0.1 nm） which is co- incident with other ones＇ results. It finds that the low-resolution structure models obtained by making use of ab initio reconstruction methods are fitting the crystal structure of human serum albumin very well. All of these results perform the potential of the beamline to apply to structural biology studies. The characteristics, the defects, and the improving measures of the station in future are also discussed.
文摘目的探讨术前C反应蛋白与白蛋白比值(C-reactive protein to albumin ratio,CAR)对非小细胞肺癌(non-small cell lung cancer,NSCLC)患者预后的预测价值。方法选取自2017年8月~2019年7月于南京医科大学附属苏州医院接受肺癌根治术的300例NSCLC患者的临床资料,通过受试者工作特征(receiver operating characteristic,ROC)曲线确定最佳临界值,分为高CAR组和低CAR组,分析不同CAR表达水平的NSCLC患者临床病理特征,采用Kaplan-Meier法绘制生存曲线并用Log-rank检验评估差异,COX比例风险模型分析影响NSCLC预后的因素。结果术前CAR预测NSCLC患者预后的ROC曲线下面积(area under the curve,AUC)为0.710,临界值为0.02。CAR与年龄、病理类型、T分期、是否淋巴结转移、临床分期、肿瘤直径、是否行术后化疗相关(P<0.05)。CAR低水平组患者总生存期(overall survival,OS)与无病生存期(disease-free survival,DFS)均长于CAR高水平组,差异有统计学意义(P<0.001)。COX多因素风险回归显示,CAR升高是NSCLC患者OS、DFS的独立危险因素(P<0.05)。结论术前CAR可作为非小细胞肺癌患者有效的预后指标,CAR升高提示预后不良。
